Tenascin C clone T2H5

Instructions For Use

Specification:
Tenascin C is a multifunctional, disulfide-linkedhexameric extracellular matrix glycoprotein expressed in association with mesenchymal epithelial interactions during development and in the neo-vasculature and stroma of undifferentiated tumors. In adults, it is restricted to certain epithelial-stromal interfaces and increases markedly in hyper-proliferative diseases and in stroma of many neoplasms, including gliomas, breast, squamous and lung carcinomas.

Availability:

Catalog No.	Contents	Volume
ILM2533-C01	Tenascin C	0,1 ml concentrate
ILM2533-C05	Tenascin C	0,5 ml concentrate
ILM2533-C1	Tenascin C	1,0 ml concentrate



Intended use: For Research Use Only

Reactivity: Human. Does not react with Rat

Clone: T2H5

Species of origin: Mouse

Isotype: IgG1/K

Control Tissue: Colon carcinoma, abortive tissue, hyperproliferative skin, tonsil.

Staining: Connective tissue matrix

Immunogen: Human breast carcinoma

Presentation: Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide

Application and suggested dilutions:
Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution 1:50-1:100)

The optimal dilution for a specific application should be determined by the investigator.

Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

References:

1) Verstraeten AA, et. al. British Journal of Dermatology, 1992, 127(6):571-4.
2) Brechbuhl HM *et al.* Fibroblast subtypes define a metastatic matrisome in breast cancer. *JCI Insight* 5:N/A (2020).
3) Molina-Molina *et al.* Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. *BMC Pulm Med* 18:63 (2018).
4) Valnegri *et al.* RNF8/UBC13 ubiquitin signaling suppresses synapse formation in the mammalian brain. *Nat Commun* 8:1271 (2017).
5) Uchimura *et al.* Insulin-Like Growth Factor II (IGF-II) Inhibits IL-1ß-Induced Cartilage Matrix Loss and Promotes Cartilage Integrity in Experimental Osteoarthritis. *J Cell Biochem* 116:2858-69 (2015).
6) Razafsky D & Hodzic A variant of Nesprin1 giant devoid of KASH domain underlies the molecular etiology of autosomal recessive cerebellar ataxia type I. *Neuobiol Dis* 78:57-67 (2015).
7) Estany S *et al.* Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFß1. *BMC Pulm Med* 14:120 (2014).
8) Fouda GG *et al.* Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. *Proc Natl Acad Sci U S A* 110:18220-5 (2013*)*
9) Seifert AW *et al.* Skin shedding and tissue regeneration in African spiny mice (Acomys). *Nature 489:561-5 (2012).*
10) Singh *et al.* Can lineage-specific markers be identified to characterize mesenchyme-derived cell populations in the human airways? *Am J Physiol Lung Cell Mol Physiol* 299:169-83 (2010).
11) Xiong W *et al.* Tenascin-C as a prognostic biomarker in osteosarcoma? *Chin Med J (Engl) 122:2737-43 (2009).*
12) Gulubova M Immunohistochemical localization of collagen type III and type IV, laminin, tenascin and alpha-smooth muscle actin (alphaSMA) in the human liver in peliosis. *Pathol Res Pract 198:803 (2002).*
13) loachim E *et al.* Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. *Eur J Cancer* 38:2362-70 (2002).
14) Faustino AM *et al.* Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. *J Comp Pathol* 126:1-8 (2002).
15) Tokes AM *et al.* Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. *Anticancer Res* 19-175-9 (1999).